NY-FLEXTRADE-SYSTEMS
9.2.2015 20:41:35 CET | Business Wire | Pressemeddelelse
FlexTrade Systems, Inc., a global leader in multi-asset execution and order management systems, today announced its Derivix OEMS has won the “Best Options Trading Platform - Vendor” category at the fourth annual Wall Street Letter Institutional Trading Awards 2015 ceremony, which was held at Cipriani in New York on February 4.
The WSL Awards are designed for brokers, exchanges and trading platforms operating within the institutional trading industry who have proved themselves over the course of the preceding year.
“It’s truly an honor to have the Derivix OEMS recognized in this options trading category,” said Vijay Kedia, President and CEO of FlexTrade. “The platform is a best-of-breed, integrated solution combining FlexTrade’s FlexOPT functionality with Derivix, an advanced, real-time analytics and portfolio risk management system acquired by the company in 2012. It is available in two versions -- Derivix -AM for the Buy-Side and Derivix-SM for the Sell-Side -- and is in use at multiple trading firms on both sides of the client spectrum.”
Following are key features available with FlexTrade’s Derivix OEMS:
Execution Management (EMS)
- Configurable multi-asset trading front-end with in-bound and out-bound FIX gateway interfaces for DMA and execution algos
- Rules‐based trading supporting user defined custom algorithmic trading parameters
- The ability to trade directly from the options matrix
- Integrated smart order routing and sweeping
- Access Volatility Trader, our proprietary volatility pegging algo that allows users to send orders based on a specified volatility or one tied to the volatility of other products
- Volatility pairs trading, Gamma scalping and Delta Hedging
- Vega trading – trade strips of options based on volatility
- Pre- & Post-Trade Risk Analysis
- Staging blotter and street order blotter
- Broker-neutral execution for the buy-side
- Customizable trade tickets
Order Management (OMS)
- Fully hosted, out-of-the-box solution that facilitates management of all types of customer orders over their entire life-cycle.
- Customizable view of historic trading activity
- Multi-asset configurability
Pricing and Analytics
- Extensive Scenario Analysis
- Proprietary Volatility Time Model
- Comprehensive Greeks and Advanced Volatility Skew Analysis
- OTC derivatives support
- Implied and user‐defined volatility management for accurate theoretical valuation
Portfolio Risk Management
- Scenario Analysis
- Grouping
- P&L Greek Decomposition
- A non‐trading version is available for risk managers who need to monitor risk across multiple asset classes from all traders under their supervision.
About FlexTrade Systems, Inc.
Founded in 1996, FlexTrade Systems, Inc. is the industry pioneer in broker-neutral algorithmic trading platforms for equities, foreign exchange and listed derivatives. With offices in North America, Europe and Asia, FlexTrade has a worldwide client base spanning more than 175 buy-side and sell-side firms, including many of the largest investment banks, hedge funds, asset managers, commodity trading advisors and institutional brokers. For more information, visit FlexTrade Systems at www.flextrade.com or follow news of the company on Twitter at www.twitter.com/flextrade or LinkedIn at http://www.linkedin.com/company/flextrade?trk=top_nav_home .
Contact:
FlexTrade Systems, Inc.
James Tolve
Tel:
516-304-3601
Cell: 516-395-0549
james.tolve@flextrade.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum